Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
FCX Freeport-McMoRan Inc
EFX Equifax Inc
CHKP Check Point Software Technologies Ltd
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Price
Delayed
$10.78
Day's Change
0.28 (2.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.04
Day's Low
10.30
Volume
(Heavy Day)

Today's volume of 2,476,110 shares is on pace to be much greater than INO's 10-day average volume of 6,395,172 shares.

2,476,110

Latest Earnings (Year ending 12/2019)

-$1.21
Consensus estimate
-$1.08

Latest Earnings Estimate Range

Highest
estimate
-$1.06
Mean
estimate
-$1.08
Lowest
estimate
-$1.09

Annual Consensus Estimates and Ranges

INO's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.